Advertisement

Topics

Pfizer and Astellas Announce Positive Late-Stage Results for Xtandi in Non-Metastatic Castration-Resistance Prostate Cancer

10:04 EDT 14 Sep 2017 | Speciality Pharma Journal

NEW YORK & TOKYO–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS). …

Original Article: Pfizer and Astellas Announce Positive Late-Stage Results for Xtandi in Non-Metastatic Castration-Resistance Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Pfizer and Astellas Announce Positive Late-Stage Results for Xtandi in Non-Metastatic Castration-Resistance Prostate Cancer"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...